Search Job Title Only
Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
November 16, 2012 at 14:03 PM EST
Investors Still Waiting for Decision on Amarin Fish-Oil Drug Exclusivity
MINYANVILLE ORIGINAL Since Amarin (NASDAQ:AMRN) won US approval for its fish-oil heart drug in late July there have been two topics of intense interest surrounding the company: Will it be taken over and will the new heart medicine Vascepa win a coveted protection for added market exclusivity? Investors are still waiting for answers. Amarin CEO Joseph Zakrzewski has said a takeover of the company is one of three paths for the company as it looks to launch Vascepa early next year. The drug is a pure fish-oil treatment -- more potent than over-the-counter products -- aimed at lowering triglycerides ...
Read More >>
AMARIN SP ADR
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Bots go here